Click For Photo: https://cdn01.dailycaller.com/wp-content/uploads/2019/02/chuck-grassley-senate-finance-e1551217453734.jpg
Republican Iowa Sen. Chuck Grassley reminded seven pharmaceutical company executives that drug list prices matter to patients during a Senate Finance Committee hearing on drug prices Thursday.
“For a patient taking a drug that has no competition, the list price becomes very important,” committee chairman Grassley said, according to NPR. “I’ve heard about people skipping doses of their prescription drugs to make them last until the next paycheck.”
Grassley - Committee - Member - Oregon - Sen
Grassley and the committee’s ranking member, Democratic Oregon Sen. Ron Wyden, questioned executives from companies including Johnson & Johnson, AstraZeneca and Pfizer at Thursday’s hearing.
“Last year, Janssen invested $8.4 billion globally in research and development, making Janssen one of the top research and development investors in any industry anywhere in the world,” said Jennifer Taubert, worldwide chairwoman of pharmaceuticals for Johnson & Johnson, which owns Janssen, according to NPR.
Wyden - Grassley - Executives - List - Prices
Wyden and Grassley continued to press the executives for high list prices, even as the CEOs responded by saying list price does not always equate to what patients pay.
“Prescription drugs did not become outrageously expensive by accident,” Wyden...
Wake Up To Breaking News!